V
IONS icon

Veritable’s Ionis Pharmaceuticals IONS Stock Holding History

Veritable’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,879
Closed -$240K – 729
2015
Q4 		$240K Sell
3,879
-2,466
-39% -$133K 0.01% 645
2015
Q3 		$256K Sell
6,345
-945
-13% -$48.9K 0.01% 610
2015
Q2 		$420K Sell
7,290
-863
-11% -$54.9K 0.01% 504
2015
Q1 		$519K Buy
8,153
+150
+2% +$10.2K 0.01% 597
2014
Q4 		$494K Buy
8,003
+424
+6% +$20.9K 0.01% 608
2014
Q3 		$294K Buy
7,579
+411
+6% +$14.6K 0.01% 780
2014
Q2 		$247K Sell
7,168
-14
-0.2% -$441 0.01% 821
2014
Q1 		$310K Buy
7,182
+14
+0.2% +$679 0.01% 720
2013
Q4 		$286K Buy
7,168
+420
+6% +$15K 0.01% 733
2013
Q3 		$253K Buy
+6,748
New +$202K 0.01% 785

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Veritable's IONS Position: Q1 2016 in Review

Veritable sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 3,879 shares — an estimated $240K sold.

Veritable first reported a position in IONS in Q3 2013 and held it in 10 quarters. The position peaked at $519K in Q1 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

  • Veritable reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Veritable sold 3,879 Ionis Pharmaceuticals shares in Q1 2016, an estimated $240K.
  • Veritable first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 10 quarters.
  • Veritable's Ionis Pharmaceuticals position peaked at $519K in Q1 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Veritable's 13F filing for Q1 2016, filed 16 May 2016.